Mode
Text Size
Log in / Sign up

MAGGIC Score Predicts Mortality Outcomes in Patients Undergoing Mitral Valve Transcatheter Edge to Edge RepairNew scoring system helps predict heart failure surgery risks

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
The MAGGIC score independently predicts 1- and 3-year mortality in FMR and DMR patients following M-TEER.

This registry analysis evaluated the prognostic utility of the MAGGIC score among 3,609 patients undergoing transcatheter edge-to-edge repair (M-TEER). The study specifically examined cohorts with both functional (FMR) and degenerative mitral regurgitation (DMR) to determine if the scoring system could outperform traditional risk models.

Results indicated that patients in the highest MAGGIC score tertile faced significantly higher risks of all-cause mortality. In the FMR cohort, those in the third tertile showed a marked increase in one-year and three-year death rates compared to lower tertiles. Similarly, the DMR cohort exhibited elevated risk profiles for both all-cause and cardiovascular deaths over the follow-up period.

When compared against established models like STS, EuroSCORE II, MitraScore, and COAPT, the MAGGIC score showed comparable or superior performance in predicting outcomes. These findings suggest that the MAGGIC score is a robust clinical tool for risk stratification in patients undergoing M-TEER procedures.

How this fits prior evidence

This finding addresses a gap in identifying specific risk predictors for patients undergoing mitral valve transcatheter edge-to-edge repair (M-TEER). While prior evidence notes that ICM-guided congestion management identifies high-risk patients for clinical events, this study provides a different predictive tool using the MAGGIC score to identify mortality risks specifically following M-TEER in both FMR and DMR populations.

When a patient needs heart surgery, doctors need the best tools possible to understand the risks involved. For those with mitral regurgitation—a condition where a heart valve doesn't close properly—predicting outcomes is vital for planning care. Researchers analyzed data from over 3,600 patients who underwent a specific type of valve repair called M-TEER.

The study looked at a tool called the MAGGIC score to see how well it predicted death over one and three years. The results showed that the MAGGIC score was highly effective. In both groups of patients studied, those with higher scores faced a significantly higher risk of death compared to those with lower scores.

This new scoring system performed as well as, or even better than, several other established models used by doctors today. While this study was an observation of existing records rather than a new treatment trial, it provides a clearer way for doctors to assess patient risk before they go into surgery.

What this means for you:
The MAGGIC score effectively predicts death risks for patients undergoing specific heart valve repairs.

Common questions

What is the MAGGIC score used for?

The MAGGIC score is a tool used to predict the risk of death after a specific type of heart valve repair called M-TEER. The study found that this score works well for both patients with functional mitral regurgitation and those with degenerative mitral regurgitation.

How accurate was the MAGGIC score compared to other methods?

The MAGGIC score performed as well as, or even better than, several standard risk models. These include the Society of Thoracic Surgeons score, the European System for Cardiac Operative Risk Evaluation II, MitraScore, and COAPT score.

What did the study find regarding patient outcomes?

Patients in the highest MAGGIC score group showed a higher risk of death at both one and three years. For example, in one group, the risk of all-cause death was over four times higher at one year for those with high scores.

Study Details

Study typeMeta analysis
Sample sizen = 3,609
EvidenceLevel 1
Follow-up12.0 mo
PublishedJul 2026
View Original Abstract ↓
BACKGROUND: The prognostic value of the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score in patients undergoing mitral valve transcatheter edge-to-edge repair (M-TEER) remains unclear. This study evaluated the MAGGIC score to predict outcomes after M-TEER in patients with functional (FMR) or degenerative mitral regurgitation (DMR) and compared its performance with conventional surgical and M-TEER-specific risk models. METHODS: We analyzed 3609 patients (FMR, 71%; DMR, 29%) who underwent M-TEER in the OCEAN (Optimized Catheter Valvular Intervention)-Mitral registry. Patients were stratified into MAGGIC score tertiles. The primary outcome was all-cause death at 1 and 3 years. Secondary outcomes included cardiovascular death. Predictive performance was compared with Society of Thoracic Surgeons score, European System for Cardiac Operative Risk Evaluation II, MitraScore, and COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) score. RESULTS: The median age was 81 years, 55.3% were men, and median MAGGIC score was 30. In the FMR cohort, patients in tertile 3 had higher risks of all-cause death (1 year: adjusted hazard ratio [HR], 4.15 [95% CI, 2.34-7.36]; 3 years: HR, 1.83 [95% CI, 1.22-2.77]) and cardiovascular death (1 year: HR, 2.31 [95% CI, 1.56-3.43]; 3 years: HR, 1.61 [95% CI, 1.13-2.31]). In the DMR cohort, tertile 3 was associated with higher all-cause death (1 year: HR, 2.84 [95% CI, 1.18-6.86]; 3 years: HR, 2.25 [95% CI, 1.07-4.73]) and cardiovascular death at 3 years (HR, 3.49 [95% CI, 1.23-9.84]). The MAGGIC score demonstrated comparable or superior discrimination on the basis of the concordance index. CONCLUSIONS: The MAGGIC score independently predicted 1- and 3-year all-cause death after M-TEER in both FMR and DMR cohorts and cardiovascular death in the FMR cohort and at 3 years in the DMR cohort. It demonstrated comparable or superior predictive performance to conventional surgical and M-TEER-specific risk models.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.